{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:27Z","timestamp":1790666967831,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00467-018-4145-6","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T03:57:53Z","timestamp":1542081473000},"page":"353-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-3705","authenticated-orcid":false,"given":"Shuichiro","family":"Fujinaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sakuraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"4145_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"key":"4145_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266","journal-title":"J Am Soc Nephrol"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","volume":"23","author":"M Nakayama","year":"2008","unstructured":"Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481\u2013485","journal-title":"Pediatr Nephrol"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5:2207\u20132212","journal-title":"Clin J Am Soc Nephrol"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28:257\u2013264","journal-title":"Pediatr Nephrol"},{"key":"4145_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","volume":"29","author":"K Kamei","year":"2014","unstructured":"Kamei K, Okada M, Sato M, Fujimaru T, Ogura M, Nakayama M, Kaito H, Iijima K, Ito S (2014) Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 29:1181\u20131187","journal-title":"Pediatr Nephrol"},{"key":"4145_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117\u20131124","journal-title":"J Am Soc Nephrol"},{"key":"4145_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","volume":"197","author":"M Jellouli","year":"2018","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T (2018) Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review. J Pediatr 197:191\u2013197","journal-title":"J Pediatr"},{"key":"4145_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.5414\/CN107336","volume":"77","author":"D Hirano","year":"2012","unstructured":"Hirano D, Fujinaga S, Nishizaki N (2012) The uncertainty of rituximab and steroid dosing in refractory steroid-resistant nephrotic syndrome. Clin Nephrol 77:510\u2013512","journal-title":"Clin Nephrol"},{"key":"4145_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13312-017-0996-3","volume":"54","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Sakuraya K (2017) Repeated administrations of rituximab along with steroids and immunosuppressive agents in refractory steroid-resistant nephrotic syndrome. Indian Pediatr 54:49\u201350","journal-title":"Indian Pediatr"},{"key":"4145_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric Nephrology; Japanese Society for Pediatric Nephrology (2015) Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19:6\u201333","journal-title":"Clin Exp Nephrol"},{"key":"4145_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K (2010) Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 25:539\u2013544","journal-title":"Pediatr Nephrol"},{"key":"4145_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T (2017) Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol 21:671\u2013676","journal-title":"Clin Exp Nephrol"},{"key":"4145_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/CN108835","volume":"85","author":"S Fujinaga","year":"2016","unstructured":"Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340\u2013345","journal-title":"Clin Nephrol"},{"key":"4145_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2015) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 30:91\u201396","journal-title":"Nephrol Dial Transplant"},{"key":"4145_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238\u20131249","journal-title":"Br J Clin Pharmacol"},{"key":"4145_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/ijn.IJN_240_16","volume":"28","author":"N Prasad","year":"2018","unstructured":"Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, Kaul A, Sharma R, Gupta A (2018) Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: a prospective study. Indian J Nephrol 28:46\u201352","journal-title":"Indian J Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4145-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:21:16Z","timestamp":1573586476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4145-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4145-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"22 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and\/or national research committee at which the study was conducted with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.All patients and their parents provided written informed consent. The use of RTX in patients with refractory SR\/SDNS in this study was approved by the ethics committee of the aforementioned center (approved number at Saitama Children\u2019s Medical Center, 2007-03-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}